Rajasekhar Jaladi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rajasekhar Jaladi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Danika Rodrigues
John A. Paulson School of Engineering and Applied Sciences, Harvard University
1 shared publication - Eden E. L. Tanner
University of Mississippi
1 shared publication - Jayoung Kim
Department of Pharmaceutical Sciences College of Pharmacy and Health Professions University of North Texas Health Fort Worth Fort Worth TX USA
1 shared publication Kelly Ibsen
Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Allston, MA 02134
1 shared publicationPradip K. Sasmal
Proprietary Products, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India
1 shared publication- Samir Mitragotri
Harvard John A. Paulson School of Engineering and Applied Sciences Harvard University Allston Massachusetts USA
1 shared publication
Latest Publications
- Open Access
- 23 February 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (9)
A deep eutectic-based, self-emulsifying subcutaneous depot system for apomorphine therapy in Parkinson’s disease
Significance: Parkinson’s disease (PD) is a progressive disorder of the central nervous system that affects motor control. While subcutaneous injection of apomorphine (Apokyn) is clinically used to alleviate intermittent episodes of dyskinesia, the treatment requires multiple injections of the drug per day, significantly deterring patient compliance. We introduce a deep eutectic-based ternary solvent system that self-emulsifies in situ following subcutaneous injection and entraps apomorphine, allowing a 48-h duration of detectable drug concentration in the plasma of pigs, which is a remarkable improvement over the clinical comparator. The results from the animal studies support the self-emulsifying system as a potent, long-lasting therapeutic for PD patients and potentially for other therapeutics that have a similar delivery challenge.
- 23 February 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (9)
Open AccessA deep eutectic-based, self-emulsifying subcutaneous depot system for apomorphine therapy in Parkinson’s disease
Significance: Parkinson’s disease (PD) is a progressive disorder of the central nervous system that affects motor control. While subcutaneous injection of apomorphine (Apokyn) is clinically used to alleviate intermittent episodes of dyskinesia, the treatment requires multiple injections of the drug per day, significantly deterring patient compliance. We introduce a deep eutectic-based ternary solvent system that self-emulsifies in situ following subcutaneous injection and entraps apomorphine, allowing a 48-h duration of detectable drug concentration in the plasma of pigs, which is a remarkable improvement over the clinical comparator. The results from the animal studies support the self-emulsifying system as a potent, long-lasting therapeutic for PD patients and potentially for other therapeutics that have a similar delivery challenge.